Unlocking new approaches for Multiple Sclerosis

Understanding why the brain fails to repair itself and exploring new treatment possibilities.
Researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS.

Unlocking new approaches for Multiple Sclerosis

July 1, 2026
Understanding why the brain fails to repair itself and exploring new treatment possibilities.
Read Transcript

The challenge

Multiple Sclerosis (MS) is a chronic neurological condition affecting more than 2.9 million people worldwide, including more than 37,000 people in Australia.1 It occurs when the body’s own immune system mistakenly attacks myelin, the protective layer that surrounds and supports nerve cells. 

When myelin is damaged, messages between the brain and body can become disrupted, causing symptoms such as fatigue, pain, mobility challenges and cognitive difficulties. For many people living with MS, symptoms can be unpredictable and change over time, while the gradual loss of function can have a significant impact on independence and quality of life. While existing treatments can help manage aspects of MS, many people continue to experience disease progression. A major unanswered question remains: why does the brain fail to repair damaged myelin? 

Dr Samantha Barton and her team at The Florey are working to answer this question by developing a first-of-its-kind “mini-brain” model that allows them to study how immune cells from people living with MS interact with myelin and affect the brain’s natural repair processes.

The role of philanthropy

Funding from Hearts & Minds has supported The Florey and allowed this research team to develop new and exciting research models to understand myelin repair in the context of MS. Using advanced stem cell technology, researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS. This allows the team to study how a person’s immune cells from their blood interacts with immune cells in their brain and whether this communication is altered in a person with MS. Understanding how immune cells talk to each other, and to myelinating cells in the brain, will hopefully uncover a way that we can generate treatments to promote myelin repair in people with MS.

Hearts & Minds support has enabled the team to establish this approach and progress to asking the key questions around how immune cells impact myelin repair in MS. The funding has also supported a multidisciplinary team spanning stem cell biology, neuroscience and immunology, helping build new collaborations and strengthen The Florey’s capacity to pursue future research opportunities in neurodegenerative disease.

What this could unlock

A deeper understanding of how immune cells disrupt myelin repair could reveal new insights into why the brain’s natural repair processes fail in MS. This research approach could help researchers identify potential targets for future therapies designed to protect or restore myelin. Ultimately, this work aims to contribute to future treatments that could slow the neurological decline experienced by many people living with MS.

Funding support from Hearts & Minds. This content was last updated in July 2026. For further information, visit The Florey.

¹ Source: MS Australia, Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025.

The challenge

Multiple Sclerosis (MS) is a chronic neurological condition affecting more than 2.9 million people worldwide, including more than 37,000 people in Australia.1 It occurs when the body’s own immune system mistakenly attacks myelin, the protective layer that surrounds and supports nerve cells. 

When myelin is damaged, messages between the brain and body can become disrupted, causing symptoms such as fatigue, pain, mobility challenges and cognitive difficulties. For many people living with MS, symptoms can be unpredictable and change over time, while the gradual loss of function can have a significant impact on independence and quality of life. While existing treatments can help manage aspects of MS, many people continue to experience disease progression. A major unanswered question remains: why does the brain fail to repair damaged myelin? 

Dr Samantha Barton and her team at The Florey are working to answer this question by developing a first-of-its-kind “mini-brain” model that allows them to study how immune cells from people living with MS interact with myelin and affect the brain’s natural repair processes.

The role of philanthropy

Funding from Hearts & Minds has supported The Florey and allowed this research team to develop new and exciting research models to understand myelin repair in the context of MS. Using advanced stem cell technology, researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS. This allows the team to study how a person’s immune cells from their blood interacts with immune cells in their brain and whether this communication is altered in a person with MS. Understanding how immune cells talk to each other, and to myelinating cells in the brain, will hopefully uncover a way that we can generate treatments to promote myelin repair in people with MS.

Hearts & Minds support has enabled the team to establish this approach and progress to asking the key questions around how immune cells impact myelin repair in MS. The funding has also supported a multidisciplinary team spanning stem cell biology, neuroscience and immunology, helping build new collaborations and strengthen The Florey’s capacity to pursue future research opportunities in neurodegenerative disease.

What this could unlock

A deeper understanding of how immune cells disrupt myelin repair could reveal new insights into why the brain’s natural repair processes fail in MS. This research approach could help researchers identify potential targets for future therapies designed to protect or restore myelin. Ultimately, this work aims to contribute to future treatments that could slow the neurological decline experienced by many people living with MS.

Funding support from Hearts & Minds. This content was last updated in July 2026. For further information, visit The Florey.

¹ Source: MS Australia, Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.